Shanghai YingLi Pharmaceutical Co. Ltd.
Shanghai YingLi Pharmaceutical Co. Ltd.
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS | Advanced Solid Tumors | Recruiting | Phase 1 | 2025-04-09 | NCT06096974 | |
| A Study of AK-1286 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Not yet recruiting | Phase 1 | 2025-01-16 | NCT06779045 | |
| YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2024-10-29 | NCT06662669 | |
| A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Not yet recruiting | Phase 2 / Phase 3 | 2024-08-12 | NCT06548347 | |
| A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor | Advanced Solid Tumors | Not yet recruiting | Phase 1 / Phase 2 | 2023-09-07 | NCT06026501 |